AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01981200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training in AECOPD
Description: The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
Study NCT01611051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Pegylated rhG-CSF: 100µg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study NCT01611051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 6mg
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study NCT01611051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF 5ug/kg/day
Description: Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study NCT00552630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: d-penicillamine
Description: d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
Study NCT00552630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo with same characteristics as drug
Study NCT00868218 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14
Study NCT05097508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium Besylate
Description: Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
Study NCT05097508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
Study NCT05097508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entropy
Description: No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
Study NCT05097508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: train of four
Description: After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
Study NCT00410826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00410826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00410826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00410826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 35 fractions
Study NCT00410826 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: 35 fractions
Study NCT00410826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: 35 fractions
Study NCT00410826 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: 35 fractions
Study NCT00410826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00410826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00785551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given in one dose to healthy subjects
Study NCT00785551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given as one dose to subjects with mild renal impairment
Study NCT00785551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given as one dose to subjects with moderate renal impairment
Study NCT04416529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-MBCT
Description: Please see arm/group description.
Study NCT04535713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study NCT04535713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study NCT04535713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Study NCT04535713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg i.v. on Day 1 beginnning Cycle 2+
Study NCT01342965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib was supplied as tablets.
Study NCT01342965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin and gemcitabine were locally sourced with commercial products.
Study NCT02306304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Duplex ultra sound screening for abdominal aortic aneurysms
Description: Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
Study NCT04783649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Papanicolaou cytological test
Description: Cervical smear stained using conventional Papanicolaou technique.
Study NCT04783649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Local cytological test (H&E stain)
Description: Cervical smear stained using conventional hematoxylin and eosin staining techniques
Study NCT04783649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Validated HPV DNA Test
Description: Digene HC2 HPV DNA Test
Study NCT04783649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Local HPV test
Description: RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
Study NCT04783649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colposcopy
Description: Women with positive cytology results are referred to colposcopy and biopsy
Study NCT01274780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir / Ritonavir + Tenofovir / Emtricitabine
Description: oral, 800/100 mg, qd + oral, 300/200 mg, qd
Study NCT01274780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
Description: oral, 300/100 mg, qd + oral, 300/200 mg, qd
Study NCT02813642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma osteoprotegerin level
Description: dosage of plasma osteoprotegerin
Study NCT02813642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 level
Description: dosage of plasma fibroblast growth factor 23
Study NCT02813642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular calcification score
Description: measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Study NCT00603070 — intervention group
Intervention type: OTHER
Intervention: E-prescribing system
Description: Transition from home-grown to vendor-based ambulatory e-prescribing systems
Study NCT00603070 — intervention group
Intervention type: OTHER
Intervention: Electronic transmission of medication discharge lists
Description: Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
Study NCT00681980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 15 mg/kg/day
Study NCT00681980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: costicosteroids
Description: metypredsolone 1 g/day
Study NCT00681980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproid acid plus corticosteroids
Description: valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
Study NCT00350623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
Study NCT00350623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
Study NCT00350623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
Study NCT04126564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inner Engineering Online
Description: Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
Study NCT04126564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inner Engineering Online
Description: Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
Study NCT04126564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading a book/ journal
Description: Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
Study NCT01069107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cottage Hospital Care
Description: Care at a cottage hospital compared with care at a general hospital
Study NCT00074087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT03032367 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bedaquiline
Study NCT02723032 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OxyFrame
Description: Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
Study NCT04793243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
Study NCT00997906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin,
Description: Given IV
Study NCT02020876 — intervention group
Intervention type: OTHER
Intervention: DECIPHER Questionnaire
Description: Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
Study NCT04081961 — intervention group
Intervention type: DEVICE
Intervention: Anamed OEM device; Air Next mobile spirometry device
Description: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
Study NCT02254785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
Study NCT02254785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000mg daily (oral) until disease progression
Study NCT02254785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide 160mg daily (oral)
Description: Enzalutamide 160mg daily (oral) until disease progression
Study NCT03445910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin
Description: intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
Study NCT06495840 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00723866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BtxA+mCIMT
Description: The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
Study NCT00723866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BtxA+ conventional rehabilitation
Description: The control group received for 2 hours/day, 3 days/week for 3 months.
Study NCT01572909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendavia (MTP-131)
Description: 0.05 mg/kg/hr
Study NCT01572909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing placebo
Study NCT01089959 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole
Description: 40 mg daily for 7 days
Study NCT01089959 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole
Description: 40 mg. daily, oral medication, once daily for 7 days.
Study NCT02703909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Study NCT02656888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irlanda-1-Association
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Study NCT02656888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Study NCT01130597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Active investigational drug
Study NCT01130597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Study NCT00606164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin for Injection
Description: A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
Study NCT00606164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single one-hour intravenous infusion of placebo on Day 1
Study NCT02518672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG-DHA
Description: MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
Study NCT02518672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
Study NCT04496284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification via slush nitrogen
Description: blastocyst stage embryos will be vitrified via slush nitrogen
Study NCT01793948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT01793948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01793948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01793948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00738764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDL192
Description: Humanized anti-TWEAK receptor monoclonal IgG1 antibody
Study NCT02703909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Study NCT02703909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Study NCT02703909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Study NCT00410046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel (etanercept)
Description: Etanercept 50 mg SC injection once weekly
Study NCT01479153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization of the site for catheterization
Description: Ultra-sound guided insertion strongly recommended
Study NCT01059786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: 28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Study NCT01059786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Study NCT00948324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII,ALA,MET,RSG
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.